|
|
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) |
|
Price: $4.3600
$-0.08 
-1.802%
|
| Day's High:
| $4.45
| Week Perf:
| -3.75 %
|
| Day's Low: |
$ 4.30 |
30 Day Perf: |
-5.83 % |
| Volume (M): |
330 |
52 Wk High: |
$ 6.75 |
| Volume (M$): |
$ 1,439 |
52 Wk Avg: |
$4.87 |
| Open: |
$4.45 |
52 Wk Low: |
$3.46 |
|
|
| Market Capitalization (Millions $) |
254 |
| Shares
Outstanding (Millions) |
58 |
| Employees |
240 |
| Revenues (TTM) (Millions $) |
191 |
| Net Income (TTM) (Millions $) |
-16 |
| Cash Flow (TTM) (Millions $) |
-83 |
| Capital Exp. (TTM) (Millions $) |
1 |
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals is a biopharmaceutical company that is focused on developing a range of products for the treatment of central nervous system disorders. The company is headquartered in Washington, DC, and was founded in 2002 by Mihael H. Polymeropoulos and Argeris N. Karabelas.
The company has a deep pipeline of products that includes both small molecules and biologics. Its lead product is Fanapt, which is the first and only FDA-approved drug for the treatment of schizophrenia. It is also developing a range of products for the treatment of other neurological disorders such as Huntington's disease, jet lag, and sleep disorders.
Vanda Pharmaceuticals is known for its innovative approach to drug development, using cutting-edge technology and scientific methods to create new products that have the potential to transform the lives of patients. The company's researchers draw on a range of disciplines, including genetics, neurobiology, and pharmacology, to find new targets and develop new drugs.
Over the years, Vanda Pharmaceuticals has received numerous awards and recognitions for its work. In 2010, the company was recognized as one of the fast-growing private companies in the US by Inc. Magazine. In 2013, it received the Ernst & Young Entrepreneur of the Year Award.
The company has a strong financial position, with a market capitalization of approximately $800 million as of 202 Its stock is traded on the NASDAQ exchange under the symbol VNDA.
In terms of its corporate culture, Vanda Pharmaceuticals is committed to creating a supportive and collaborative work environment. The company values diversity, and its employees come from a range of backgrounds and nationalities. It is also committed to giving back to the community, with a focus on supporting healthcare initiatives and promoting education and scientific research.
Overall, Vanda Pharmaceuticals is an important player in the biopharmaceutical industry, with a reputation for innovation, scientific excellence, and a commitment to improving the lives of patients.
Company Address: 2200 Pennsylvania Avenue NW Washington 20037 DC
Company Phone Number: 734-3400 Stock Exchange / Ticker: NASDAQ VNDA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc. recently reported a significant increase in losses for the most recent fiscal period, with the company's net deficit per share rising to $-0.07 from $0.06 in the previous period. This increase in losses was primarily attributed to weak business performance, with revenue decreasing by -24.058% to $47.46 million from $62.50 million a year prior.
In contrast to Vanda Pharmaceuticals Inc., the rest of the Major Pharmaceutical Preparations industry saw a 2.49% improvement in revenue relative to the first quarter of 2023 in the first quarter of 2024. However, Vanda Pharmaceuticals Inc. experienced a 4.84% increase in revenue from $45.27 million in the previous quarter, although the company still reported an increased deficit of $-0.04 per share.
|
| Vanda Pharmaceuticals Inc
The stock market is always a constant source of excitement and anticipation for investors. It's a world of ups and downs, where fortunes are made and lost in the blink of an eye. As we delve into the financial reports of Vanda Pharmaceuticals Inc, we can gain some valuable insights into the current state of affairs and what the future holds for this pharmaceutical giant.
The Dec 31, 2023 report paints a picture of a company facing challenges, with weak orders leading to an increase in losses. The shortfall per share advanced at $-0.04 from $0.12, indicating a decline in profitability. Furthermore, revenue dropped by a significant -29.793% to $45.27 million from $64.48 million in the previous year. These numbers might seem discouraging at first glance, but a closer look reveals some positive developments.
|
| Vanda Pharmaceuticals Inc
Financial news report:
Vanda Pharmaceuticals Inc (VNDA) recently reported its financial results for the time-frame ending September 30, 2023. The company reached a break-even point of $0.00 per share, compared to $0.06 per share a year earlier and $0.03 per share in the previous reporting period. While the company managed to break even, its revenue declined significantly. The revenue dropped by -40.575% to $38.82 million, compared to $65.32 million in the same reporting period last year. Sequentially, the revenue fell by -15.722% from $46.06 million.
The net income for the financial time-frame ending September 30, 2023, was $0.137 million, which represents a decline of -95.81% from $3.270 million in the corresponding period a year ago. Analysts note that the situation for Vanda Pharmaceuticals Inc would have been even worse if not for the $0.26 million income tax benefit, which helped to limit the downturn to -95.81%.
|
| Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc, a leading pharmaceutical company, recently released its financial report for the fiscal time-frame ending June 30, 2023. The report reveals a decline in company income per share, profit, and revenue compared to the previous reporting period.
According to the report, company income per share dropped by 40% to $0.03 per share, down from $0.05 per share in the same period a year prior. Profit also plummeted by 50%, falling from $0.06 per share in the prior reporting period. These figures suggest that the company's financial performance has weakened over the past year.
|
| Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc has released its financial report for the first quarter of 2023, revealing a return on average invested assets (ROI) of 2.98%. While this is below the company's average ROI of 14.17%, it is an improvement from the previous quarter.
The report also showed that Vanda Pharmaceuticals Inc's net income has deteriorated, but the company has seen progress in ROI ranking, moving up from 1897 in Q4 2022 to 441 in Q1 2023. Within the healthcare sector, 34 other companies had a higher ROI during this periodIn terms of financial performance, Vanda Pharmaceuticals Inc recorded positive earnings of $0.06 per share, a significant improvement from the negative earnings of $-0.11 per share from the previous year. However, profits have declined by 49.31% from $0.12 per share from the preceding reporting period.
Revenue increased modestly by 3.831% to $62.50 million from $60.19 million in the same reporting period a year ago, but sequentially revenue decreased by -3.077% from $64.48 million. Vanda Pharmaceuticals Inc also reported net profits of $3.252 million in the most recent fiscal period, an improvement versus a net loss of $-6.430 million in the same period last year. The company emphasized its improving profit margins, with a net margin of 5.2% and an operating margin of 3.21%.
Vanda Pharmaceuticals Inc is expected to report its next financial earnings on May 5, 2023.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.28 $ |
| Revenues (TTM) |
3.28 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.72 $
|
| Book Value |
9.29 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.28 $
|
| Revenues (TTM) |
3.28 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.72 $
|
| Book Value |
9.29 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
3.95%